- Home
- CLX vs BBIO Comparison
CLX vs BBIO Comparison
Compare CLX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLX | BBIO |
|---|---|---|
| Founded | 1913 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 15.3B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLX | BBIO |
|---|---|---|
| Price | $104.41 | $77.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 25 |
| Target Price | ★ $114.83 | $86.04 |
| AVG Volume (30 Days) | ★ 2.0M | 1.5M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.75% | N/A |
| EPS Growth | ★ 189.78 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $6,124,000,000.00 | $502,076,000.00 |
| Revenue This Year | N/A | $88.16 |
| Revenue Next Year | $7.64 | $74.13 |
| P/E Ratio | $54.11 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $96.66 | $31.77 |
| 52 Week High | $143.96 | $84.94 |
Technical Indicators
Market Signals| Indicator | CLX | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 63.67 |
| Support Level | $98.99 | $70.65 |
| Resistance Level | $108.18 | $81.33 |
| Average True Range (ATR) | 2.99 | 2.47 |
| MACD | 0.58 | 0.70 |
| Stochastic Oscillator | 50.73 | 88.00 |
Price Performance
Historical ComparisonAbout CLX Clorox Company (The)
Since its inception more than 100 years ago, Clorox has expanded to operate in a variety of consumer product categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.